Strategic partnerships ProMab Biotechnologies has recent and ongoing partnerships focused on CAR-T, CAR-NK, and antibody engineering with entities like Cytion GmbH and Tebubio GmbH, indicating a receptive ecosystem for collaboration and co-development opportunities in engineered cell therapies and diagnostic tools.

mRNA-LNP services The company highlights a new service offering in mRNA-LNP product and services to address emerging infectious diseases, presenting a clear entry point for sales teams to cross-sell related reagents, regulatory support, and custom mRNA-LNP solutions to biotech and pharma clients developing vaccines or therapeutics.

Hematology focus Historically active in antibody and CAR-T therapies for hematological malignancies with collaborations involving L-DOS47 and immune checkpoint inhibitors, suggesting strong demand for targeted biologics, assay development, and preclinical model services in blood cancers.

Tooling ecosystem ProMab’s portfolio spans recombinant proteins, antibodies, engineered cell lines, and ready-to-use CAR constructs and non-viral mRNA-LNP technologies, enabling cross-sell of research reagents, custom cell lines, and turnkey immunotherapy toolkits to labs and CROs.

Growth indicators With revenue in the mid-range six figures to low seven figures and a lean employee base, the company appears scalable and actively investing in advanced capabilities, signaling opportunities for strategic investments, distributor partnerships, and regional expansion to broaden market reach.